🇺🇸 FDA

Intelligence · Clinical Pipeline

Metabolic & obesity R&D Pipeline

GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Programs
755

Quick answer

Metabolic & obesity: NovaPharmaNews indexes 755 metabolic & obesity clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Top sponsors

Page 11 of 16

  1. A study investigating the safety of RO7795081 and the effect of RO7795081 on how the body processes different approved medications. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control

    Hoffmann-La Roche

    Obesity or Overweight

    phase 1 other active

    1 trial

  2. A study investigating the safety, absorption, and elimination of NNC0705-0001, a new compound that could potentially be used in the treatment of cardiometabolic diseases caused by inflammation.

    NovoThirteen

    Cardiometabolic diseases with an inflammatory component

    phase 1 other active

    1 trial

  3. A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  4. A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity

    Hoffmann-La Roche

    Healthy volunteers

    phase 1 other active

    1 trial

  5. A study investigating the safety, absorption, and elimination of RO7795081, a new compound that may potentially be used in the treatment of type 2 diabetes and weight control

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  6. A study of how CagriSema works on appetite in people with excess body weight

    NovoThirteen

    Obesity

    phase 1 other active

    1 trial

  7. A study to assess the pharmacokinetics, and glucodynamics of LY3209590 in participants with type 2 diabetes

    Eli Lilly Co.

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  8. A study to see the effect of NNC0194-0499 alone or in combination with semaglutide on blood sugar control in people living with type 1 diabetes.

    NovoThirteen

    Diabetes mellitus type 1

    phase 1 other active

    1 trial

  9. A study to test how a new long-acting insulin works in the body of patients with type 2 diabetes during exercise and prolonged fasting.

    NovoThirteen

    Type 2 diabetes

    phase 1 other active

    1 trial

  10. A study to test how insulin NNC0471-0119 H works in the body in participants with type 1 diabetes when given by an insulin pump.

    NovoThirteen

    Diabetes mellitus type 1

    phase 1 other active

    1 trial

  11. A study to test how insulin NNC0471-0119 works in the body in participants with type 2 diabetes when given by an insulin pump.

    NovoThirteen

    Diabetes mellitus type 2

    phase 1 other active

    1 trial

  12. A study to test how well different doses of BI 3034701 are tolerated by healthy men and people with overweight or obesity

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  13. A study to test how well different doses of BI 3804379 are tolerated by healthy people and patients with MASH

    Boehringer Ingelheim

    Metabolic Dysfunction-associated Steatohepatitis

    phase 1 other active

    1 trial

  14. A study to test whether BI 456906 (survodutide) influences the amount of bupropion, caffeine and midazolam in the blood in people with overweight or obesity

    Boehringer Ingelheim

    Overweight, Obesity

    phase 1 other active

    1 trial

  15. A study to test whether multiple doses of BI 456906 have an effect on cardiac safety in people with overweight or obesity.

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  16. ALG-055009

    Aligos Therapeutics

    NASH - Nonalcoholic Steatohepatitis

    phase 1 small molecule completed

    1 trial

  17. ALN-PNP

    Regeneron UK Limited

    Nonalcoholic Fatty Liver Disease (NAFLD)

    phase 1 small molecule completed

    1 trial

  18. ALT-801

    Timmune Biotech

    Obesity

    phase 1 small molecule completed

    1 trial

  19. Administration of UI087

    United Therapeutics Europe Ltd

    Diabetes Mellitus (Type 2)

    phase 1 small molecule active

    1 trial

  20. An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Empagliflozin Tablets 25 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Jardiance (Empagliflozin) 25 mg film-coated tablets, Marketing Authorisation Holder Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein Germany, in healthy adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Diabetes

    phase 1 other active

    1 trial

  21. Aramchol

    Galmed Pharmaceuticals

    NASH

    phase 1 small molecule completed

    1 trial

  22. Autologous differentiated myocyte transplantation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metabolic Disease

    phase 1 mab active

    1 trial

  23. BCX7353 and probes

    Biocryst

    Hereditary Angioedema

    phase 1 small molecule completed

    1 trial

  24. Bioequivalence clinical trial of dapagliflozin 10 mg tablets, after a single oral dose administration to healthy volunteers under fasting conditions.

    Laboratorios Tillomed Spain S.L.U

    Diabetes

    phase 1 other active

    1 trial

  25. Busulfan Fresenius Kabi 6 mg/ml concentrate for solution for infusion, Neupogen 30 MU (0,6 mg/ml) solución inyectable en jeringa precargada filgrastim, Mozobil 20 mg/ml solution for injection, Merilen

    Lacuna Pharma Pty Ltd

    Inherited metabolic disorder of the enzyme pyruvate kinase which affects the survival of red blood cells, Pyruvate Kinase Deficiency

    phase 1 small molecule active

    1 trial

  26. C19-A3 GNP

    Cardiff Oncology

    Type 1 Diabetes

    phase 1 small molecule completed

    1 trial

  27. CKD-371

    Hong Kong Baptist University

    Type II Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  28. CKD-393 formulation I

    Hong Kong Baptist University

    Type II Diabetes

    phase 1 small molecule completed

    1 trial

  29. CM-101

    Chemomab Therapeutics

    Nonalcoholic Steatohepatitis (NASH)

    phase 1 small molecule completed

    1 trial

  30. CRB-913

    Corbus Pharmaceuticals Holdings

    Obese But Otherwise Healthy Participants

    phase 1 small molecule active

    1 trial

  31. CT-996

    The First People's Hospital of Lianyungang

    Type 2 Diabetes

    phase 1 small molecule completed

    1 trial

  32. Camel milk containing Bifidobacterium animalis A6

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Type 2 Diabetes

    phase 1 other completed

    1 trial

  33. Clinical research trial for evaluating different properties, such as safety, tolerability and body interaction, of a new drug called ALY688ER, administered as subcutaneous injection in healthy overweight or obese people.

    Lacuna Pharma Pty Ltd

    NASH

    phase 1 other active

    1 trial

  34. DFUPS

    United Therapeutics Europe Ltd

    Diabetic Foot

    phase 1 other completed

    1 trial

  35. Dose escalation of SA030

    Suzhou Ribo Life Science Co.

    Obese

    phase 1 small molecule active

    1 trial

  36. Drug 601

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Diabetic Macular Edema

    phase 1 small molecule active

    1 trial

  37. EDP 305

    ENANTA PHARMACEUTICALS INC

    NASH

    phase 1 small molecule completed

    1 trial

  38. EDP 305

    ENANTA PHARMACEUTICALS INC

    Presumptive NAFLD

    phase 1 small molecule completed

    1 trial

  39. EDP-297

    ENANTA PHARMACEUTICALS INC

    NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis

    phase 1 small molecule completed

    1 trial

  40. EDP-305

    ENANTA PHARMACEUTICALS INC

    NASH - Nonalcoholic Steatohepatitis

    phase 1 small molecule completed

    2 trials

  41. Empagliflozin 10 MG Oral Tablet [Jardiance]

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  42. Erythromycin lactobionate

    ADIAL PHARMACEUTICALS, INC.

    Diabetes Mellitus, Type 1

    phase 1 small molecule completed

    1 trial

  43. FT-003

    The First People's Hospital of Lianyungang

    Diabetic Macular Edema

    phase 1 gene therapy active

    1 trial

  44. Faster Aspart

    Novo Nordisk A/S

    Diabetes Mellitus, Type 1

    phase 1 small molecule completed

    1 trial

  45. Fluconazole

    ENANTA PHARMACEUTICALS INC

    NASH - Nonalcoholic Steatohepatitis

    phase 1 small molecule completed

    1 trial

  46. GR-MD-02

    GALECTIN THERAPEUTICS INC

    Non-Alcoholic Steatohepatitis (NASH)

    phase 1 small molecule completed

    1 trial

  47. Garetosmab

    Regeneron UK Limited

    Obesity

    phase 1 small molecule terminated

    1 trial

  48. Glucagon

    United Therapeutics Europe Ltd

    Type 1 Diabetes Mellitus With Hypoglycemia

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many metabolic & obesity pipeline programs are tracked?

755 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.